CooperCompanies keeps CooperSurgical and approves buyback of CooperCompanies stock
Published on 10/25/2026 at 01:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and capital allocation
- CooperCompanies completed its strategic review on September 9, 2026, and approved a USD 3.00 billion repurchase plan.
- Fiscal third-quarter revenue reached USD 1.066 billion, while earnings per share came to USD 1.15.
- CooperCompanies expects its next report on December 3, 2026.
CooperCompanies (ISIN US2166485019) approved a USD 3.00 billion share-repurchase plan on September 9, 2026, while keeping CooperSurgical inside the group, according to Yahoo Finance. The decision followed a strategic review that concluded the offers received did not reflect the business's long-term value.
What does the review mean for growth?
The fiscal third-quarter review produced a mixed operating picture. Consolidated revenue was USD 1.066 billion, while earnings per share reached USD 1.15, compared with a USD 1.12 consensus estimate, according to MarketBeat. The earnings comparison gives management room to invest, but CooperVision's channel inventory reduction weighed on revenue execution.
Management said CooperVision revenue was USD 717 million and CooperSurgical revenue was USD 349 million in fiscal third quarter 2026. Fertility revenue reached USD 141 million, up 5.00 percent organically, while the company used cash generation to repurchase USD 339 million of shares during the quarter, according to Yahoo Finance.
Three events shaped the stock
On September 9, 2026, CooperCompanies reported fiscal third-quarter earnings per share of USD 1.15 and authorized a USD 3.00 billion buyback. On October 15, 2026, Piper Sandler reiterated a Neutral rating and set a USD 59.00 target, according to Investing.com. On October 23, 2026, traders bought 2,270 call options, 121.00 percent above the typical daily volume, according to MarketBeat.
Dates for the next checkpoint
CooperCompanies expects its next report on December 3, 2026, according to Forecaster. The fiscal fourth-quarter outlook calls for consolidated revenue of USD 1.057 billion to USD 1.08 billion and earnings per share of USD 1.05 to USD 1.09, with CooperVision revenue expected at USD 692 million to USD 706 million.
Capital returns meet execution risk
CooperCompanies had a market capitalization of USD 11.6 billion on October 23, 2026. The core investor question is whether stronger commercial execution can convert the company's contract wins and product launches into revenue growth while the buyback supports capital returns.
The further course of trading is shown by the continuously updated real-time quote of CooperCompanies stock.
CooperCompanies stock facts
- Company: The Cooper Companies, Inc.
- ISIN: US2166485019
- Ticker: COO
- Primary exchange: Nasdaq
- Market capitalization: USD 11.6 billion (as of October 23, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: S&P 500
Market context: Market report S&P 500.
